Clinical Trials
24
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females
- Conditions
- Bone Mineral Density
- Interventions
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Duramed Research
- Target Recruit Count
- 1361
- Registration Number
- NCT00924560
- Locations
- 🇺🇸
Teva Investigational Site 007, Phoenix, Arizona, United States
🇺🇸Teva Investigational Site 018, Phoenix, Arizona, United States
🇺🇸Teva Investigational Site 005, Tucson, Arizona, United States
A Safety Extension Study of DR-OXY-301
- Conditions
- Overactive Bladder
- Interventions
- Drug: Oxybutinyn Vaginal Ring 4mgDrug: Oxybutinyn Vaginal Ring 6mg
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Duramed Research
- Target Recruit Count
- 240
- Registration Number
- NCT00782769
- Locations
- 🇺🇸
Duramed Investigational Site, Tacoma, Washington, United States
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
- Conditions
- Migraine
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Duramed Research
- Target Recruit Count
- 109
- Registration Number
- NCT00781456
- Locations
- 🇺🇸
Teva Investigational Site, Houston, Texas, United States
🇺🇸Duramed Investigational Site, Seattle, Washington, United States
Emergency Contraception Actual Use Study
- Conditions
- Emergency Contraception
- Interventions
- Drug: DR-104
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Duramed Research
- Target Recruit Count
- 343
- Registration Number
- NCT00777556
- Locations
- 🇺🇸
Duramed Research Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸Teva Investigational Site, Pittsburgh, Pennsylvania, United States
A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- Drug: DR-3001Drug: Placebo
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Duramed Research
- Target Recruit Count
- 1104
- Registration Number
- NCT00685113
- Locations
- 🇨🇦
Duramed Investigational Site, Thunder Bay, Ontario, Canada
🇺🇸Duramed Investigation Site, Decatur, Georgia, United States
🇨🇦Duramed Investigatinal Site, Vancouver, British Columbia, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- Next